Brusatol may serve as potential adjuvant therapy for pancreatic ductal adenocarcinoma

Announcing a new publication for Acta Materia Medica journal. Chemoresistance to gemcitabine (Gem) remains a substantial obstacle in the treatment of pancreatic ductal adenocarcinoma carcinoma (PDAC).

Pharma budget tightening trickles down to Doximity

You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in

August 10, 2023

Daré’s royalty deal; Qlaris Bio raises $24M

Plus, news about Newron and SynOx: Daré Bioscience inks royalty deal with XOMA: The company received $22 million, which is expected to help progress a

May 1, 2024

Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement – Biotech Investments

Takeda Pharmaceutical Company Limited / Key word(s): Strategic Company Decision Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating

May 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.